Verrica Pharmaceuticals Inc. Payment for Debt Extinguishment or Debt Prepayment Cost
Verrica Pharmaceuticals Inc. (VRCA) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2025-12-31 was $870.00K.
- Verrica Pharmaceuticals Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2025-09-30 was $3.89M.
- Verrica Pharmaceuticals Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2025 was $12.79M.
- Verrica Pharmaceuticals Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2024 was $0.00.
- Verrica Pharmaceuticals Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Verrica Pharmaceuticals Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2022 was $43.75M.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 6 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $870.00K derived: sum of 3 quarters · filed 2026-08-06 | $4.76M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $870.00K derived: sum of 2 quarters · filed 2026-05-12 | $4.76M derived: sum of 3 quarters · filed 2026-05-12 | $8.83M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $870.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $4.76M derived: sum of 2 quarters · filed 2026-03-11 | $8.83M derived: sum of 3 quarters · filed 2026-08-06 | $12.79M 10-K · filed 2026-03-11 | |
| 2025-09-30 | $3.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $7.96M derived: sum of 2 quarters · filed 2026-08-06 | $11.92M 10-Q · filed 2025-11-14 | $11.92M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $4.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $8.03M 10-Q · filed 2026-08-06 | $8.03M derived: sum of 3 quarters · filed 2026-08-06 | $8.03M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $3.96M 10-Q · filed 2026-05-12 | $3.96M derived: sum of 2 quarters · filed 2026-05-12 | $3.96M derived: sum of 3 quarters · filed 2026-05-12 | $3.96M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | $0.00 derived: sum of 3 quarters · filed 2026-03-11 | $0.00 10-K · filed 2026-03-11 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | $0.00 10-K · filed 2024-02-29 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $43.75M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $43.75M 10-Q · filed 2022-11-07 | ||||
| 2022-07-11 | $43.80M 10-K · filed 2024-02-29 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |